Skip to main content
Top
Published in: BMC Cancer 1/2005

Open Access 01-12-2005 | Research article

Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines

Authors: Gregory M Loewen, Erin Tracy, Frédéric Blanchard, Dongfeng Tan, Jihnhee Yu, Sameera Raza, Sei-Ichi Matsui, Heinz Baumann

Published in: BMC Cancer | Issue 1/2005

Login to get access

Abstract

Background

Inflammation is commonly associated with lung tumors. Since inflammatory mediators, including members of the interleukin-6 (IL-6) cytokine family, suppress proliferation of normal epithelial cells, we hypothesized that epithelial cells must develop mechanisms to evade this inhibition during the tumorigenesis. This study compared the cytokine responses of normal epithelial cells to that of premalignant cells.

Methods

Short-term primary cultures of epithelial cells were established from bronchial brushings. Paired sets of brushings were obtained from areas of normal bronchial epithelium and from areas of metaplastic or dysplastic epithelium, or areas of frank endobronchial carcinoma. In 43 paired cultures, the signalling through the signal transducer and activator of transcription (STAT) and extracellular regulated kinase (ERK) pathways and growth regulation by IL-6, leukemia inhibitory factor (LIF), oncostatin M (OSM), interferon-γ (IFNγ) or epidermal growth factor (EGF) were determined. Inducible expression and function of the leukemia inhibitory factor receptor was assessed by treatment with the histone deacetylase inhibitor depsipeptide.

Results

Normal epithelial cells respond strongly to OSM, IFNγ and EGF, and respond moderately to IL-6, and do not exhibit a detectable response to LIF. In preneoplastic cells, the aberrant signaling that was detected most frequently was an elevated activation of ERK, a reduced or increased IL-6 and EGF response, and an increased LIF response. Some of these changes in preneoplastic cell signaling approach those observed in established lung cancer cell lines. Epigenetic control of LIF receptor expression by histone acetylation can account for the gain of LIF responsiveness. OSM and macrophage-derived cytokines suppressed proliferation of normal epithelial cells, but reduced inhibition or even stimulated proliferation was noted for preneoplastic cells. These alterations likely contribute to the supporting effects that inflammation has on lung tumor progression.

Conclusion

This study indicates that during the earliest stage of premalignant transformation, a modified response to cytokines and EGF is evident. Some of the altered cytokine responses in primary premalignant cells are comparable to those seen in established lung cancer cell lines.
Appendix
Available only for authorised users
Literature
1.
go back to reference Driscoll KE, Carter JM, Howard BW, Hassenbein DG, Pepelko W, Baggs RB, Oberdorster G: Pulmonary inflammatory, chemokine, and mutagenic responses in rats after subchronic inhalation of carbon black. Toxicol Appl Pharmacol. 1996, 136: 372-380. 10.1006/taap.1996.0045.CrossRefPubMed Driscoll KE, Carter JM, Howard BW, Hassenbein DG, Pepelko W, Baggs RB, Oberdorster G: Pulmonary inflammatory, chemokine, and mutagenic responses in rats after subchronic inhalation of carbon black. Toxicol Appl Pharmacol. 1996, 136: 372-380. 10.1006/taap.1996.0045.CrossRefPubMed
2.
go back to reference Ardies CM: Inflammation as cause for scar cancers of the lung. Integr Cancer Ther. 2003, 2: 238-246. 10.1177/1534735403256332.CrossRefPubMed Ardies CM: Inflammation as cause for scar cancers of the lung. Integr Cancer Ther. 2003, 2: 238-246. 10.1177/1534735403256332.CrossRefPubMed
3.
go back to reference Philip M, Rowley DA, Schreiber H: Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004, 14: 433-439. 10.1016/j.semcancer.2004.06.006.CrossRefPubMed Philip M, Rowley DA, Schreiber H: Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004, 14: 433-439. 10.1016/j.semcancer.2004.06.006.CrossRefPubMed
4.
go back to reference Lam S, Kennedy T, Unger M, Miller YE, Gelmont D, Rusch V, Gipe B, Howard D, LeRiche JC, Coldman A, Gazdar AF: Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest. 1998, 113: 696-702.CrossRefPubMed Lam S, Kennedy T, Unger M, Miller YE, Gelmont D, Rusch V, Gipe B, Howard D, LeRiche JC, Coldman A, Gazdar AF: Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest. 1998, 113: 696-702.CrossRefPubMed
5.
go back to reference Saccomanno G, Archer VE, Auerbach O, Saunders RP, Brennan LM: Development of carcinoma of the lung as reflected in exfoliated cells. Cancer. 1974, 33: 256-270.CrossRefPubMed Saccomanno G, Archer VE, Auerbach O, Saunders RP, Brennan LM: Development of carcinoma of the lung as reflected in exfoliated cells. Cancer. 1974, 33: 256-270.CrossRefPubMed
6.
go back to reference Auerbach O, Saccomanno G, Kuschner M, Brown RD, Garfinkel L: Histologic findings in the tracheobronchial tree of uranium miners and non-miners with lung cancer. Cancer. 1978, 42: 483-489.CrossRefPubMed Auerbach O, Saccomanno G, Kuschner M, Brown RD, Garfinkel L: Histologic findings in the tracheobronchial tree of uranium miners and non-miners with lung cancer. Cancer. 1978, 42: 483-489.CrossRefPubMed
7.
go back to reference Bota S, Auliac JB, Paris C, Metayer J, Sesboue R, Nouvet G, Thiberville L: Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med. 2001, 164: 1688-1693.CrossRefPubMed Bota S, Auliac JB, Paris C, Metayer J, Sesboue R, Nouvet G, Thiberville L: Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med. 2001, 164: 1688-1693.CrossRefPubMed
8.
go back to reference Hirsch FR, Prindiville SA, Miller YE, Franklin WA, Dempsey EC, Murphy JR, Bunn PA, Kennedy TC: Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst. 2001, 93: 1385-1391. 10.1093/jnci/93.18.1385.CrossRefPubMed Hirsch FR, Prindiville SA, Miller YE, Franklin WA, Dempsey EC, Murphy JR, Bunn PA, Kennedy TC: Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst. 2001, 93: 1385-1391. 10.1093/jnci/93.18.1385.CrossRefPubMed
9.
go back to reference Breuer RH, Pasic A, Smit EF, van Vliet E, Vonk Noordegraaf A, Risse EJ, Postmus PE, Sutedja TG: The natural course of preneoplastic lesions in bronchial epithelium. Clin Cancer Res. 2005, 11: 537-543.PubMed Breuer RH, Pasic A, Smit EF, van Vliet E, Vonk Noordegraaf A, Risse EJ, Postmus PE, Sutedja TG: The natural course of preneoplastic lesions in bronchial epithelium. Clin Cancer Res. 2005, 11: 537-543.PubMed
10.
go back to reference Knaapen AM, Borm PJ, Albrecht C, Schins RP: Inhaled particles and lung cancer. Part A: Mechanisms. Int J Cancer. 2004, 109: 799-809. 10.1002/ijc.11708.CrossRefPubMed Knaapen AM, Borm PJ, Albrecht C, Schins RP: Inhaled particles and lung cancer. Part A: Mechanisms. Int J Cancer. 2004, 109: 799-809. 10.1002/ijc.11708.CrossRefPubMed
11.
go back to reference Emmendoerffer A, Hecht M, Boeker T, Mueller M, Heinrich U: Role of inflammation in chemical-induced lung cancer. Toxicol Lett. 2000, 112–113: 185-191. 10.1016/S0378-4274(99)00285-4.CrossRefPubMed Emmendoerffer A, Hecht M, Boeker T, Mueller M, Heinrich U: Role of inflammation in chemical-induced lung cancer. Toxicol Lett. 2000, 112–113: 185-191. 10.1016/S0378-4274(99)00285-4.CrossRefPubMed
12.
go back to reference Grant SL, Begley CG: The oncostatin M signalling pathway: reversing the neoplastic phenotype?. Mol Med Today. 1999, 5: 406-412. 10.1016/S1357-4310(99)01540-3.CrossRefPubMed Grant SL, Begley CG: The oncostatin M signalling pathway: reversing the neoplastic phenotype?. Mol Med Today. 1999, 5: 406-412. 10.1016/S1357-4310(99)01540-3.CrossRefPubMed
13.
go back to reference Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, Hirano T, Horn F, Behrmann I: Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene. 1999, 18: 3742-3753. 10.1038/sj.onc.1202708.CrossRefPubMed Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, Hirano T, Horn F, Behrmann I: Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene. 1999, 18: 3742-3753. 10.1038/sj.onc.1202708.CrossRefPubMed
14.
go back to reference Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003, 374: 1-20. 10.1042/BJ20030407.CrossRefPubMedPubMedCentral Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003, 374: 1-20. 10.1042/BJ20030407.CrossRefPubMedPubMedCentral
15.
go back to reference Kim H, Baumann H: Dual signalling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol. 1999, 19: 5326-5338.CrossRefPubMedPubMedCentral Kim H, Baumann H: Dual signalling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol. 1999, 19: 5326-5338.CrossRefPubMedPubMedCentral
16.
go back to reference Blanchard F, Wang Y, Kinzie E, Duplomb L, Godard A, Baumann H: Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem. 2001, 276: 47038-47045. 10.1074/jbc.M107971200.CrossRefPubMed Blanchard F, Wang Y, Kinzie E, Duplomb L, Godard A, Baumann H: Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem. 2001, 276: 47038-47045. 10.1074/jbc.M107971200.CrossRefPubMed
17.
go back to reference Loewen G, Reid M, Tan D, Klippenstein D, Nava E, Natarajan R, Mahoney M: Bimodality Lung Cancer Screening in High risk Patients. Chest. 2004, 125: 163s-164s. 10.1378/chest.125.5_suppl.163S-a.CrossRefPubMed Loewen G, Reid M, Tan D, Klippenstein D, Nava E, Natarajan R, Mahoney M: Bimodality Lung Cancer Screening in High risk Patients. Chest. 2004, 125: 163s-164s. 10.1378/chest.125.5_suppl.163S-a.CrossRefPubMed
18.
go back to reference Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E: World Health Organization classification of lung and pleural tumors. 1999, Springer Verlag Berlin, Germany Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E: World Health Organization classification of lung and pleural tumors. 1999, Springer Verlag Berlin, Germany
19.
go back to reference Matsui S., Sait S, Jones CA, Nowak N, Gross KW: Rapid localization of transgenes in mouse chromosomes using a combined Spectral Karyotyping/FISH technique. Mammalian Genome. 2002, 13: 680-685. 10.1007/s00335-002-2197-0.CrossRefPubMed Matsui S., Sait S, Jones CA, Nowak N, Gross KW: Rapid localization of transgenes in mouse chromosomes using a combined Spectral Karyotyping/FISH technique. Mammalian Genome. 2002, 13: 680-685. 10.1007/s00335-002-2197-0.CrossRefPubMed
20.
go back to reference Tan D, Kirley S, Li Q, Ramnath R, Slocum H, Brooks J, Wu CL, Zukerberg L: Loss of Cables Protein Expression in Human Non-Small Cell Lung Cancer: A Tissue Microarray Study. Human Pathol. 2003, 34: 143-149. 10.1053/hupa.2003.26.CrossRef Tan D, Kirley S, Li Q, Ramnath R, Slocum H, Brooks J, Wu CL, Zukerberg L: Loss of Cables Protein Expression in Human Non-Small Cell Lung Cancer: A Tissue Microarray Study. Human Pathol. 2003, 34: 143-149. 10.1053/hupa.2003.26.CrossRef
21.
go back to reference Bepler G, Koehler A, Kiefer P, Havemann K, Beisenherz K, Jaques G, Gropp C, Haeder M: Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation. 1988, 37: 158-171.CrossRefPubMed Bepler G, Koehler A, Kiefer P, Havemann K, Beisenherz K, Jaques G, Gropp C, Haeder M: Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation. 1988, 37: 158-171.CrossRefPubMed
22.
go back to reference Blanchard F, Kinzie E, Wang Y, Duplomb L, Godard A, Held WA, Asch BB, Baumann H: FR90 an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Oncogene. 1228, 21: 6264-6277. 10.1038/sj.onc.1205777.CrossRef Blanchard F, Kinzie E, Wang Y, Duplomb L, Godard A, Held WA, Asch BB, Baumann H: FR90 an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Oncogene. 1228, 21: 6264-6277. 10.1038/sj.onc.1205777.CrossRef
23.
go back to reference Douglas WG, Tracy E, Tan D, Yu J, Hicks WL, Rigual NR, Loree TR, Wang Y, Baumann H: Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. Mol Cancer Res. 2004, 2: 585-593.PubMed Douglas WG, Tracy E, Tan D, Yu J, Hicks WL, Rigual NR, Loree TR, Wang Y, Baumann H: Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. Mol Cancer Res. 2004, 2: 585-593.PubMed
24.
go back to reference Franklin WA, Fokvord JM, Varella-Garcia M, Kennedy T, Proudfoot S, Cook R, Dempsey EC, Helm K, Bunn PA, Miller YE: Expansion of bronchial epithelial cell populations by in vitro culture of explants from dysplastic and histologically normal sites. Am J Resp Cell Mol Biol. 1996, 15: 297-304.CrossRef Franklin WA, Fokvord JM, Varella-Garcia M, Kennedy T, Proudfoot S, Cook R, Dempsey EC, Helm K, Bunn PA, Miller YE: Expansion of bronchial epithelial cell populations by in vitro culture of explants from dysplastic and histologically normal sites. Am J Resp Cell Mol Biol. 1996, 15: 297-304.CrossRef
25.
go back to reference Blanchard F, Duplomb L, Wang Y, Robledo O, Kinzie E, Pitard V, Godard A, Jacques Y, Baumann H: Stimulation of leukemia inhibitory factor receptor degradation by extracellular signal-regulated kinase. J Biol Chem. 2000, 275: 28793-28801. 10.1074/jbc.M003986200.CrossRefPubMed Blanchard F, Duplomb L, Wang Y, Robledo O, Kinzie E, Pitard V, Godard A, Jacques Y, Baumann H: Stimulation of leukemia inhibitory factor receptor degradation by extracellular signal-regulated kinase. J Biol Chem. 2000, 275: 28793-28801. 10.1074/jbc.M003986200.CrossRefPubMed
26.
go back to reference Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, Ihle JN, Rutschman R, Murray PJ: SOCS3 regulates the plasticity of gp130 signalling. Nat Immunol. 2003, 4: 546-550. 10.1038/ni932.CrossRefPubMed Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, Ihle JN, Rutschman R, Murray PJ: SOCS3 regulates the plasticity of gp130 signalling. Nat Immunol. 2003, 4: 546-550. 10.1038/ni932.CrossRefPubMed
27.
go back to reference Mahboubi K, Kirkiles-Smith NC, Karras J, Pober JS: Desensitization of signalling by oncostatin M in human vascular cells involves cytoplasmic Tyr residue 759 in gp130 but is not mediated by either Src homology 2 domain-containing tyrosine phosphatase 2 or suppressor of cytokine signalling 3. J Biol Chem. 2003, 278: 25014-25023. 10.1074/jbc.M211867200.CrossRefPubMed Mahboubi K, Kirkiles-Smith NC, Karras J, Pober JS: Desensitization of signalling by oncostatin M in human vascular cells involves cytoplasmic Tyr residue 759 in gp130 but is not mediated by either Src homology 2 domain-containing tyrosine phosphatase 2 or suppressor of cytokine signalling 3. J Biol Chem. 2003, 278: 25014-25023. 10.1074/jbc.M211867200.CrossRefPubMed
28.
go back to reference Huber RM, Stratakis DF: Molecular oncology – perspectives in lung cancer. Lung Cancer. 2004, 45: S209-S213. 10.1016/j.lungcan.2004.07.973.CrossRefPubMed Huber RM, Stratakis DF: Molecular oncology – perspectives in lung cancer. Lung Cancer. 2004, 45: S209-S213. 10.1016/j.lungcan.2004.07.973.CrossRefPubMed
29.
go back to reference Blanchard F, Tracy E, Smith J, Chattopadhyay S, Wang Y, Held WA, Baumann H: DNA methylation controls the responsiveness of hepatoma cells to leukemia inhibitory factor. Hepatology. 2003, 38: 1516-1528.CrossRefPubMed Blanchard F, Tracy E, Smith J, Chattopadhyay S, Wang Y, Held WA, Baumann H: DNA methylation controls the responsiveness of hepatoma cells to leukemia inhibitory factor. Hepatology. 2003, 38: 1516-1528.CrossRefPubMed
30.
go back to reference Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003, 21: 3798-3807. 10.1200/JCO.2003.11.069.CrossRefPubMed Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003, 21: 3798-3807. 10.1200/JCO.2003.11.069.CrossRefPubMed
31.
go back to reference Clark J, Edwards S, Feber A, Flohr P, John M, Giddings I, Crossland S, Stratton MR, Wooster R, Campbell C, Cooper CS: Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene. 2003, 22: 1247-1252. 10.1038/sj.onc.1206247.CrossRefPubMed Clark J, Edwards S, Feber A, Flohr P, John M, Giddings I, Crossland S, Stratton MR, Wooster R, Campbell C, Cooper CS: Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene. 2003, 22: 1247-1252. 10.1038/sj.onc.1206247.CrossRefPubMed
32.
go back to reference Morrison DK, Davis RJ: Regulation of MAP kinase signalling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol. 2003, 19: 91-118. 10.1146/annurev.cellbio.19.111401.091942.CrossRefPubMed Morrison DK, Davis RJ: Regulation of MAP kinase signalling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol. 2003, 19: 91-118. 10.1146/annurev.cellbio.19.111401.091942.CrossRefPubMed
33.
go back to reference Ramakrishna G, Sithanandam G, Cheng RY, Fornwald LW, Smith GT, Diwan BA, Anderson LM: K-ras p21 expression and activity in lung and lung tumors. Exp Lung Res. 2000, 26: 659-671. 10.1080/01902140150216747.CrossRefPubMed Ramakrishna G, Sithanandam G, Cheng RY, Fornwald LW, Smith GT, Diwan BA, Anderson LM: K-ras p21 expression and activity in lung and lung tumors. Exp Lung Res. 2000, 26: 659-671. 10.1080/01902140150216747.CrossRefPubMed
34.
go back to reference Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey AJ: Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003, 17: 1263-1293. 10.1038/sj.leu.2402945.CrossRefPubMed Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey AJ: Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003, 17: 1263-1293. 10.1038/sj.leu.2402945.CrossRefPubMed
35.
go back to reference Klausen P, Pedersen L, Jurlander J, Baumann H: Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene. 2000, 19: 3675-3683. 10.1038/sj.onc.1203707.CrossRefPubMed Klausen P, Pedersen L, Jurlander J, Baumann H: Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene. 2000, 19: 3675-3683. 10.1038/sj.onc.1203707.CrossRefPubMed
36.
go back to reference Yu H, Jove R: The STATs of cancer--new molecular targets come of age. Nature Rev Cancer. 2004, 4: 97-105.CrossRef Yu H, Jove R: The STATs of cancer--new molecular targets come of age. Nature Rev Cancer. 2004, 4: 97-105.CrossRef
37.
go back to reference Lai CF, Ripperger J, Wang Y, Kim H, Hawley RB, Baumann H: The STAT3-independent signalling pathway by glycoprotein 130 in hepatic cells. J Biol Chem. 1999, 274: 7793-7802. 10.1074/jbc.274.12.7793.CrossRefPubMed Lai CF, Ripperger J, Wang Y, Kim H, Hawley RB, Baumann H: The STAT3-independent signalling pathway by glycoprotein 130 in hepatic cells. J Biol Chem. 1999, 274: 7793-7802. 10.1074/jbc.274.12.7793.CrossRefPubMed
38.
go back to reference Li C, Ahlborn TE, Kraemer FB, Liu J: Oncostatin M-induced growth inhibition and morphological changes of MDA-MB231 breast cancer cells are abolished by blocking the MEK/ERK signalling pathway. Breast Cancer Res Treat. 2001, 6: 111-121. 10.1023/A:1010614724664.CrossRef Li C, Ahlborn TE, Kraemer FB, Liu J: Oncostatin M-induced growth inhibition and morphological changes of MDA-MB231 breast cancer cells are abolished by blocking the MEK/ERK signalling pathway. Breast Cancer Res Treat. 2001, 6: 111-121. 10.1023/A:1010614724664.CrossRef
Metadata
Title
Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines
Authors
Gregory M Loewen
Erin Tracy
Frédéric Blanchard
Dongfeng Tan
Jihnhee Yu
Sameera Raza
Sei-Ichi Matsui
Heinz Baumann
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2005
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-5-145

Other articles of this Issue 1/2005

BMC Cancer 1/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine